MARKET

AVEO

AVEO

Aveo
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.53
+0.24
+3.29%
Opening 10:17 06/05 EDT
OPEN
7.51
PREV CLOSE
7.29
HIGH
7.69
LOW
7.38
VOLUME
74.41K
TURNOVER
--
52 WEEK HIGH
11.20
52 WEEK LOW
2.230
MARKET CAP
121.09M
P/E (TTM)
290.73
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average AVEO stock price target is 20.67 with a high estimate of 26.00 and a low estimate of 12.00.

EPS

AVEO News

More
Hedge Funds Never Been Less Bullish On AVEO Pharmaceuticals, Inc. (AVEO)
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite inve
Insider Monkey · 15h ago
FDA Okays AVEO's NDA Filing for Treating Renal Cell Carcinoma
Zacks · 2d ago
Aveos Tivozanib Gets FDA Nod For New Drug Application To Treat Kidney Cancer
SmarterAnalyst · 3d ago
FDA accepts Aveo application for tivozanib for kidney cancer
The FDA accepts for review AVEO Oncology's (AVEO -2.9%) marketing application seeking approval of tivozanib for relapsed/refractory renal cell carcinoma. T
seekingalpha · 3d ago
UPDATE: AVEO Says Tivozanib Assigned PDUFA Target Action Date For Mar. 31, 2021
Benzinga · 3d ago
AVEO Oncology Announces FDA Acceptance for Filing of a New Drug Application for Tivozanib as a Treatment of Relapsed or Refractory Renal Cell Carcinoma
- Tivozanib assigned PDUFA target action date of March 31, 2021; FDA indicates that it does not currently plan to convene an ODAC - AVEO Oncology (NASDAQ:AVEO) today announced that the U.S. Food and Drug Administration
Tivozanib assigned PDUFA target action date of March 31, 2021; FDA indicates that it does not currently plan to convene an ODAC - AVEO Oncology (NASDAQ:AVEO) today announced that the U.S. Food and Drug Administration · 3d ago
AVEO Oncology Announces FDA Acceptance for Filing of a New Drug Application for Tivozanib as a Treatment of Relapsed or Refractory Renal Cell Carcinoma
AVEO Oncology (NASDAQ: AVEO) today announced that the U.S. Food and Drug Administration (FDA) accepted for filing its New Drug Application (NDA) seeking approval for tivozanib, the Company’s next-generation vascular endothelial growth factor receptor tyrosine
Business Wire · 3d ago
Implied Volatility Surging for AVEO Pharmaceuticals (AVEO) Stock Options
Zacks · 4d ago

Industry

Biotechnology & Medical Research
+0.72%
Pharmaceuticals & Medical Research
+0.57%

Hot Stocks

Symbol
Price
%Change

About AVEO

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's platform delivers insights into cancer and related disease. The Company's product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors. Tivozanib is designed to optimize VEGF blockade while minimizing off-target toxicities. Ficlatuzumab is a Hepatocyte Growth Factor (HGF) inhibitory antibody. AV-203 is an anti-ErbB3 monoclonal antibody with ErbB3 affinity. Its preclinical studies suggest that neuregulin1 (NRG1) levels predict AV-203 antitumor activity in preclinical models. AV-380 is a humanized Immunoglobulin G 1 (IgG1) inhibitory monoclonal antibody. AV-380 targets growth differentiating factor 15 (GDF15).
More

Webull offers kinds of AVEO Pharmaceuticals, Inc. stock information, including NASDAQ:AVEO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVEO stock news, and many more online research tools to help you make informed decisions.